A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival
作者： Dickran Kazandjian , Ola Landgren
DOI: 10.1053/J.SEMINONCOL.2016.10.008
关键词:
摘要: The past decade has seen significant advances in our understanding and treatment of multiple myeloma (MM) its precursor diseases. These include gains knowledge the underlying pathobiology including molecular cellular prognostic factors for disease progression. In parallel we have witnessed availability novel therapeutics. Together these translated into improvements long-term clinical benefit survival MM. Indeed, it been shown that patients diagnosed last experienced almost doubling median time. We aim to review give further insight drug development approvals revolutionized
elsevier.com
sci-hub.se 参考文章(31)
Ola Landgren, Roger G. Owen, Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient. Cytometry Part B-clinical Cytometry. ,vol. 90, pp. 14- 20 ,(2016) , 10.1002/CYTO.B.21273
A Keith Stewart, S Vincent Rajkumar, Meletios A Dimopoulos, Tamás Masszi, Ivan Špička, Albert Oriol, Roman Hájek, Laura Rosiñol, David S Siegel, Georgi G Mihaylov, Vesselina Goranova-Marinova, Péter Rajnics, Aleksandr Suvorov, Ruben Niesvizky, Andrzej J Jakubowiak, Jesus F San-Miguel, Heinz Ludwig, Michael Wang, Vladimír Maisnar, Jiri Minarik, William I Bensinger, Maria-Victoria Mateos, Dina Ben-Yehuda, Vishal Kukreti, Naseem Zojwalla, Margaret E Tonda, Xinqun Yang, Biao Xing, Philippe Moreau, Antonio Palumbo, None, Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma The New England Journal of Medicine. ,vol. 372, pp. 142- 152 ,(2015) , 10.1056/NEJMOA1411321
Jeffrey A. Zonder, Ann F. Mohrbacher, Seema Singhal, Frits van Rhee, William I. Bensinger, Han Ding, John Fry, Daniel E. H. Afar, Anil K. Singhal, A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma Blood. ,vol. 120, pp. 552- 559 ,(2012) , 10.1182/BLOOD-2011-06-360552
S Yousef, J Marvin, M Steinbach, A Langemo, T Kovacsovics, M Binder, N Kröger, T Luetkens, D Atanackovic, Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients Blood Cancer Journal. ,vol. 5, ,(2015) , 10.1038/BCJ.2015.7
Shaji K. Kumar, S. Vincent Rajkumar, Angela Dispenzieri, Martha Q. Lacy, Suzanne R. Hayman, Francis K. Buadi, Steven R. Zeldenrust, David Dingli, Stephen J. Russell, John A. Lust, Philip R. Greipp, Robert A. Kyle, Morie A. Gertz, Improved survival in multiple myeloma and the impact of novel therapies Blood. ,vol. 111, pp. 2516- 2520 ,(2008) , 10.1182/BLOOD-2007-10-116129
J Schmidt, E Braggio, K M Kortuem, J B Egan, Y X Zhu, C S Xin, R E Tiedemann, S E Palmer, V M Garbitt, D McCauley, M Kauffman, S Shacham, M Chesi, P L Bergsagel, A K Stewart, Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. Leukemia. ,vol. 27, pp. 2357- 2365 ,(2013) , 10.1038/LEU.2013.172
Niina Veitonmäki, Markus Hansson, Fenghuang Zhan, Annika Sundberg, Tobias Löfstedt, Anne Ljungars, Zhan-Chun Li, Titti Martinsson-Niskanen, Ming Zeng, Ye Yang, Lena Danielsson, Mathilda Kovacek, Andrea Lundqvist, Linda Mårtensson, Ingrid Teige, Guido Tricot, Björn Frendéus, A human icam-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. Cancer Cell. ,vol. 23, pp. 502- 515 ,(2013) , 10.1016/J.CCR.2013.02.026
Paul G. Richardson, David S. Siegel, Ravi Vij, Craig C. Hofmeister, Rachid Baz, Sundar Jagannath, Christine Chen, Sagar Lonial, Andrzej Jakubowiak, Nizar Bahlis, Kevin Song, Andrew Belch, Noopur Raje, Chaim Shustik, Suzanne Lentzsch, Martha Lacy, Joseph Mikhael, Jeffrey Matous, David Vesole, Min Chen, Mohamed H. Zaki, Christian Jacques, Zhinuan Yu, Kenneth C. Anderson, Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. ,vol. 123, pp. 1826- 1832 ,(2014) , 10.1182/BLOOD-2013-11-538835
Jesús F San-Miguel, Vânia T M Hungria, Sung-Soo Yoon, Meral Beksac, Meletios Athanasios Dimopoulos, Ashraf Elghandour, Wieslaw Wiktor Jedrzejczak, Andreas Günther, Thanyaphong Na Nakorn, Noppadol Siritanaratkul, Paolo Corradini, Suporn Chuncharunee, Je-Jung Lee, Robert L Schlossman, Tatiana Shelekhova, Kwee Yong, Daryl Tan, Tontanai Numbenjapon, Jamie D Cavenagh, Jian Hou, Richard LeBlanc, Hareth Nahi, Lugui Qiu, Hans Salwender, Stefano Pulini, Philippe Moreau, Krzysztof Warzocha, Darrell White, Joan Bladé, WenMing Chen, Javier de la Rubia, Peter Gimsing, Sagar Lonial, Jonathan L Kaufman, Enrique M Ocio, Ljupco Veskovski, Sang Kyun Sohn, Ming-Chung Wang, Jae Hoon Lee, Hermann Einsele, Monika Sopala, Claudia Corrado, Bourras-Rezki Bengoudifa, Florence Binlich, Paul G Richardson, Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial Lancet Oncology. ,vol. 15, pp. 1195- 1206 ,(2014) , 10.1016/S1470-2045(14)70440-1
Stuart A. Rushworth, Kristian M. Bowles, Lawrence N. Barrera, Megan Y. Murray, Lyubov Zaitseva, David J. MacEwan, BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB. Cellular Signalling. ,vol. 25, pp. 106- 112 ,(2013) , 10.1016/J.CELLSIG.2012.09.008